Navigation Links
Novel drug in pill form safer than standard approach to treat blocked lung blood vessels
Date:3/26/2012

CHICAGO -- A novel oral anti-coagulant outperformed the injected standard therapy on important safety measures for initial and long-term treatment of pulmonary embolism a blockage of lung blood vessels usually caused by a clot and showed comparable efficacy, according to data from the EINSTEIN-PE trial presented today at the American College of Cardiology's 61st Annual Scientific Session. The Scientific Session, the premier cardiovascular medical meeting, brings cardiovascular professionals together to further advances in the field.

Pulmonary embolism (PE) and deep vein thrombosis (DVT), a blot clot generally occurring in the legs, constitute the two categories of a condition called venous thromboembolism (VTE). VTE is the third most common cardiovascular disease, and PE is the third most common cause of hospital-related death. EINSTEIN-PE is one of a series of large international phase III clinical trials of the anti-coagulant rivaroxaban to treat VTE or prevent a recurrence in patients with acute PE or DVT. The Food and Drug Administration has approved rivaroxaban as the only oral anti-coagulant for prevention of VTE in patients who have knee or hip replacement, procedures that carry clotting risks.

The trial compared rivaroxaban with standard therapy injection of the anti-coagulant enoxaparin, followed by a vitamin K antagonist (VKA; either warfarin or acenocoumarol) chosen by each participating site to demonstrate that the oral drug as a single agent is equivalent to the complicated two-drug standard therapy. In the standard regimen, enoxaparin must be given as an injection, and the VKA must be monitored with blood tests to make sure the dose is adequate and safe, because common drugs such as antibiotics, alcohol and some foods interact with VKAs. The monitoring measure is INR, an expression of the time it takes blood to clot: the higher the INR number, the higher the risk of bleeding.

"If you give standard treatment in the right way, it's a perfectly effective drug with almost 90 percent reduction in recurrent thrombosis, but it has to be well controlled," said Harry R. Buller, MD, PhD, professor of vascular medicine at the Academic Medical Center, Amsterdam, The Netherlands, who chairs the program for the three EINSTEIN studies. "The reason people look for alternatives is that it's a nightmare to give. Rivaroxaban makes things easier for everybody patients and physicians. Our major aim was to show that it's at least as good as standard care."

The study, conducted at 263 sites in 38 countries, randomly assigned 2,419 patients to the rivaroxaban arm and 2,414 to standard treatment. All enrolled patients had a primary diagnosis of PE, and 25 percent in both groups also had DVT. Patients were treated for three, six or 12 months (average, seven) as deemed appropriate by each clinician before randomization. The rivaroxaban group received 15 mg twice a day for three weeks followed by 20 mg once a day. In the standard-therapy arm, the regimen was enoxaparin at 1.0 mg per kg of body weight twice daily, continued at least five days and stopped when the INR was 2.0 or more for two consecutive days, plus a VKA started within 48 hours after randomization with dose adjustment to maintain an INR of 2.0 to 3.0.

Rivaroxaban's efficacy was highly significant for non-inferiority with 2.1 percent recurrences (50 events) vs. 1.8 percent (44 events) in the standard-therapy arm. On safety measures of bleeding, rivaroxaban did much better: principal safety measure of major or clinically relevant bleeding, 10.3 percent vs. 11.4 percent for standard treatment; for major bleeding alone, 1.1 percent vs. 2.2 percent for standard therapy. Rates for primary endpoints were similar in both study arms regardless of patient characteristics.

"Physicians want to know about major bleeding, the most important safety outcome, and rivaroxaban was highly significantly superior. This was our most astonishing finding," Dr. Buller said. "Rivaroxaban is just as good as standard treatment for PE these data are pretty convincing and this is an oral-only approach, which makes it very simple. The subcutaneous injections can be hazardous as well."

Researchers also will be doing a subgroup analysis of the 8,200 patients in the EINSTEIN-PE and EINSTEIN-DVT trials to see if they can identify a risk profile for patients who are likely to have bleeding problems on standard treatment or the new drug.


'/>"/>
Contact: Beth Casteel
bcasteel@acc.org
240-328-4549
American College of Cardiology
Source:Eurekalert

Related medicine news :

1. Novel mouse model for autism yields clues to a 50-year-old mystery
2. Unprecedented academic-industry collaboration seeks new drugs and novel treatments for autism
3. Novel plastics and textiles from waste with the use of microbes
4. UC San Diego among first in nation to treat brain cancer with novel viral vector
5. Students at Western University develop a novel way to teach interdisciplinary care
6. UH Case Medical Center publishes study on novel treatment for skin lymphoma
7. Mass. General researchers find novel way to prevent drug-induced liver injury
8. Rutgers, Massachusetts General investigators find novel way to prevent drug-induced liver injury
9. NIH scientists identify novel approach to view inner workings of viruses
10. Novel Stem Cell Treatment May Hold Promise for Type 1 Diabetes
11. KalVista and JDRF form research partnership for novel treatment of diabetic eye disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... Lebanon, NH (PRWEB) , ... January 18, 2017 ... ... the launch of the revolutionary Active Brake Technology (ABT), an innovative braking system ... stability. , Active Brake Technology addresses one of the biggest concerns of beginner ...
(Date:1/17/2017)... ... 17, 2017 , ... January is National Stalking Awareness Month (NSAM), now in its ... corners and commit the crime of stalking, a very real danger to many in our ... factor in stalking and other crimes. , “Stalking: know it. Name it. Stop it.”—so reads ...
(Date:1/17/2017)... Los Angeles, California (PRWEB) , ... January 17, ... ... essential to have a point of difference. Eden Activewear is a stand-out company ... itself. Eden are exclusively online and only manufacture on demand, this is called ...
(Date:1/17/2017)... Phoenix, AZ (PRWEB) , ... January 17, 2017 ... ... new and improved supplement, Healthful-Flex. , The company, owned and operated by ... the public at a reasonable price with the highest level of customer service. ...
(Date:1/17/2017)... ... January 17, 2017 , ... Etymotic ... National Association of Music Merchants (NAMM) winter trade show, Booth #2876, at the ... ER•4® has long been the gold standard for high-definition, in-ear earphones. This classic ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... Research and Markets has announced the addition of the "Global ... ... artificial pancreas devices system market to grow at a CAGR of ... System Market 2016-2020, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:1/17/2017)... , Jan. 17, 2017 The interventional ... billion by 2021 from USD 6.35 billion in 2016, ... driving the growth of this market are rising incidence ... for minimally invasive surgeries. The global interventional ... application, and region. On the basis of type, the ...
(Date:1/17/2017)... Management to Discuss Acquisition of Oncology ... Development On Track For An NDA Submission ... 2017   ... KTOV ; TASE: KTOV), an innovative biopharmaceutical company, announced that it ... 8:30am Eastern Time to discuss the recent acquisition of a majority stake in ...
Breaking Medicine Technology: